These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37097298)

  • 1. Effects of sodium-glucose cotransporter 2 inhibitors on renal risk factors in patients with abnormal glucose metabolism: a meta-analysis of randomized controlled trials.
    Li M; Zhang J; Yang G; Zhang J; Han M; Zhang Y; Liu Y
    Eur J Clin Pharmacol; 2023 Jun; 79(6):859-871. PubMed ID: 37097298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis.
    Akbari A; Rafiee M; Sathyapalan T; Sahebkar A
    J Diabetes Res; 2022; 2022():7520632. PubMed ID: 35224108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis.
    Wang C; Zhou Y; Kong Z; Wang X; Lv W; Geng Z; Wang Y
    Diabetes Obes Metab; 2019 Apr; 21(4):1018-1026. PubMed ID: 30565382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sodium-glucose cotransporter 2 inhibitors on insulin resistance; a systematic review and meta-analysis.
    Fakhrolmobasheri M; Abhari AP; Manshaee B; Heidarpour M; Shafie D; Mohammadbeigi E; Mozafari AM; Mazaheri-Tehrani S
    Acta Diabetol; 2023 Feb; 60(2):191-202. PubMed ID: 36264350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis.
    Li M; Yi T; Fan F; Qiu L; Wang Z; Weng H; Ma W; Zhang Y; Huo Y
    Cardiovasc Diabetol; 2022 Jul; 21(1):139. PubMed ID: 35879763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials.
    Scheen AJ
    Diabetes Metab; 2020 Jun; 46(3):186-196. PubMed ID: 32007623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of sodium-glucose cotransporter 2 inhibitors as an adjunct to insulin in patients with type 1 diabetes assessed by continuous glucose monitoring: A systematic review and meta-analysis.
    Li M; Liu Z; Yang X; Zhang J; Han M; Zhang Y; Liu Y
    J Diabetes Complications; 2023 Dec; 37(12):108632. PubMed ID: 37907042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal, cardiovascular, and safety outcomes of adding sodium-glucose cotransporter-2 inhibitors to insulin therapy in patients with type-2 diabetes: a meta-analysis.
    Zhang Q; Zhang Q; Yang L; Yang S; Lu Y
    Int Urol Nephrol; 2024 Feb; 56(2):557-570. PubMed ID: 37515749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes.
    Zhou Y; Geng Z; Wang X; Huang Y; Shen L; Wang Y
    Diabetes Metab Res Rev; 2020 Feb; 36(2):e3223. PubMed ID: 31642583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
    Liu XY; Zhang N; Chen R; Zhao JG; Yu P
    J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials.
    Rao L; Ren C; Luo S; Huang C; Li X
    Acta Diabetol; 2021 Jul; 58(7):869-880. PubMed ID: 33651228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals.
    Lin DS; Lee JK; Chen WJ
    J Clin Endocrinol Metab; 2021 Jun; 106(7):2133-2145. PubMed ID: 33895840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium Glucose Cotransporter-2 Inhibitor Protects Against Diabetic Neuropathy and Nephropathy in Modestly Controlled Type 2 Diabetes: Follow-Up Study.
    Ishibashi F; Kosaka A; Tavakoli M
    Front Endocrinol (Lausanne); 2022; 13():864332. PubMed ID: 35784562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of sodium-glucose cotransporter-2 inhibitors on continuous glucose monitoring metrics, as adjunctive to insulin in adults with type 1 diabetes mellitus: a meta-analysis of randomized controlled trials.
    Popovic DS; Karakasis P; Koufakis T; Fragakis N; Papanas N; Mitrovic M; Gouveri E; Patoulias D
    Metabolism; 2024 Apr; 153():155791. PubMed ID: 38232802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: A meta-analysis of randomized controlled trials.
    Fan G; Guo DL
    Eur J Intern Med; 2023 Aug; 114():49-57. PubMed ID: 37062643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis.
    Alexander JT; Staab EM; Wan W; Franco M; Knitter A; Skandari MR; Bolen S; Maruthur NM; Huang ES; Philipson LH; Winn AN; Thomas CC; Zeytinoglu M; Press VG; Tung EL; Gunter K; Bindon B; Jumani S; Laiteerapong N
    J Gen Intern Med; 2022 Feb; 37(2):439-448. PubMed ID: 34850334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis.
    Hu M; Cai X; Yang W; Zhang S; Nie L; Ji L
    J Am Heart Assoc; 2020 Apr; 9(7):e015323. PubMed ID: 32223390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.